Johnson & Johnson is discontinuing two CAR-T programs in B-cell lymphoma—JNJ-9530 and JNJ-4496—citing an evolving treatment landscape and portfolio priorities after phase 1 and 1/2 development. The company will continue to support patients already in trials per protocols, but the move reduces prospective competitive pressure in a space where multiple CAR-T and bispecific approaches are competing. The decision follows earlier big-company emphasis on CAR-T scale-up and reinforces how quickly asset-level strategy can shift once commercial and clinical benchmarks tighten.